Zobrazeno 1 - 10
of 333
pro vyhledávání: '"Julià, Blanco"'
Autor:
Carlos Ávila-Nieto, Júlia Vergara-Alert, Pep Amengual-Rigo, Erola Ainsua-Enrich, Marco Brustolin, María Luisa Rodríguez de la Concepción, Núria Pedreño-Lopez, Jordi Rodon, Victor Urrea, Edwards Pradenas, Silvia Marfil, Ester Ballana, Eva Riveira-Muñoz, Mònica Pérez, Núria Roca, Ferran Tarrés-Freixas, Guillermo Cantero, Anna Pons-Grífols, Carla Rovirosa, Carmen Aguilar-Gurrieri, Raquel Ortiz, Ana Barajas, Benjamin Trinité, Rosalba Lepore, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, Nuria Izquierdo-Useros, Alfonso Valencia, Julià Blanco, Victor Guallar, Bonaventura Clotet, Joaquim Segalés, Jorge Carrillo
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P
Externí odkaz:
https://doaj.org/article/417894952ca54f88947455ec8d336df7
Autor:
Carla Usai, Erola Ainsua-Enrich, Victor Urrea Gales, Edwards Pradenas, Cristina Lorca-Oró, Ferran Tarrés-Freixas, Núria Roca, Mónica Pérez, Carlos Ávila-Nieto, María Luisa Rodríguez de la Concepción, Núria Pedreño-Lopez, Julieta Carabelli, Benjamin Trinité, Ester Ballana, Eva Riveira-Muñoz, Nuria Izquierdo-Useros, Bonaventura Clotet, Julià Blanco, Victor Guallar, Guillermo Cantero, Júlia Vergara-Alert, Jorge Carrillo, Joaquim Segalés
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-12 (2024)
Abstract Age is associated with reduced efficacy of vaccines and linked to higher risk of severe COVID-19. Here we determined the impact of ageing on the efficacy of a SARS-CoV-2 vaccine based on a stabilised Spike glycoprotein (S-29) that had previo
Externí odkaz:
https://doaj.org/article/f305a783ac09456b913d3b908a30b8e8
Autor:
Leire de Campos-Mata, Benjamin Trinité, Andrea Modrego, Sonia Tejedor Vaquero, Edwards Pradenas, Anna Pons-Grífols, Natalia Rodrigo Melero, Diego Carlero, Silvia Marfil, César Santiago, Dàlia Raïch-Regué, María Teresa Bueno-Carrasco, Ferran Tarrés-Freixas, Ferran Abancó, Victor Urrea, Nuria Izquierdo-Useros, Eva Riveira-Muñoz, Ester Ballana, Mónica Pérez, Júlia Vergara-Alert, Joaquim Segalés, Carlo Carolis, Rocío Arranz, Julià Blanco, Giuliana Magri
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Here we report the characterization of 17T2, a SARS-CoV-2 pan-neutralizing human monoclonal antibody isolated from a COVID-19 convalescent individual infected during the first pandemic wave. 17T2 is a class 1 VH1-58/κ3-20 antibody, derived
Externí odkaz:
https://doaj.org/article/e88c94774f434c16bec8caaf30b4258f
Autor:
Ana Barajas, Pep Amengual-Rigo, Anna Pons-Grífols, Raquel Ortiz, Oriol Gracia Carmona, Victor Urrea, Nuria de la Iglesia, Juan Blanco-Heredia, Carla Anjos-Souza, Ismael Varela, Benjamin Trinité, Ferran Tarrés-Freixas, Carla Rovirosa, Rosalba Lepore, Miguel Vázquez, Leticia de Mattos-Arruda, Alfonso Valencia, Bonaventura Clotet, Carmen Aguilar-Gurrieri, Victor Guallar, Jorge Carrillo, Julià Blanco
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background Neoantigens are patient- and tumor-specific peptides that arise from somatic mutations. They stand as promising targets for personalized therapeutic cancer vaccines. The identification process for neoantigens has evolved with the
Externí odkaz:
https://doaj.org/article/83a923e41a4c4f16982d7a9a094b4b9c
Autor:
María Jesús López Fernández, Silvia Narejos, Antoni Castro, José María Echave-Sustaeta, María José Forner, Eunate Arana-Arri, José Molto, Laia Bernad, Raúl Pérez-Caballero, Julia G. Prado, Dàlia Raïch-Regué, Rytis Boreika, Nuria Izquierdo-Useros, Benjamin Trinité, Julià Blanco, Joan Puig-Barberà, Silvina Natalini Martínez
Publikováno v:
Vaccines, Vol 12, Iss 8, p 840 (2024)
(1) Background: The global coronavirus disease 2019 vaccination adapts to protect populations from emerging variants. This communication presents interim findings from the new Omicron XBB.1.16-adapted PHH-1V81 protein-based vaccine compared to an XBB
Externí odkaz:
https://doaj.org/article/03e5acd3e60440fba94d5eb1a33afd0f
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2
Autor:
Lorna Leal, Judit Pich, Laura Ferrer, Jocelyn Nava, Ruth Martí-Lluch, Ignasi Esteban, Edwards Pradenas, Dàlia Raïch-Regué, Antoni Prenafeta, Karla Escobar, Carmen Pastor, Marc Ribas-Aulinas, Benjamin Trinitè, Jordana Muñoz-Basagoiti, Gemma Domenech, Bonaventura Clotet, Júlia Corominas, Aida Corpes-Comes, Carme Garriga, Antonio Barreiro, Nuria Izquierdo-Useros, Joan Albert Arnaiz, Alex Soriano, José Ríos, Marga Nadal, Montserrat Plana, Julià Blanco, Teresa Prat, Elia Torroella, Rafel Ramos, HIPRA-HH-1 study group
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-12 (2023)
Abstract In response to COVID-19 pandemic, we have launched a vaccine development program against SARS-CoV-2. Here we report the safety, tolerability, and immunogenicity of a recombinant protein RBD fusion heterodimeric vaccine against SARS-CoV-2 (PH
Externí odkaz:
https://doaj.org/article/0a20f98d912343ffad1efe821c52c851
Autor:
Raquel Ortiz, Ana Barajas, Anna Pons-Grífols, Benjamin Trinité, Ferran Tarrés-Freixas, Carla Rovirosa, Víctor Urrea, Antonio Barreiro, Anna Gonzalez-Tendero, Maria Rovira-Rigau, Maria Cardona, Laura Ferrer, Bonaventura Clotet, Jorge Carrillo, Carmen Aguilar-Gurrieri, Julià Blanco
Publikováno v:
Viruses, Vol 16, Iss 6, p 987 (2024)
The envelope glycoprotein (Env) of retroviruses, such as the Feline leukemia virus (FeLV), is the main target of neutralizing humoral response, and therefore, a promising vaccine candidate, despite its reported poor immunogenicity. The incorporation
Externí odkaz:
https://doaj.org/article/28f6dcb59e8c49f0b75c64e52e01d415
Autor:
Ferran Tarrés-Freixas, Carmen Aguilar-Gurrieri, María Luisa Rodríguez de la Concepción, Victor Urrea, Benjamin Trinité, Raquel Ortiz, Edwards Pradenas, Pau Blanco, Sílvia Marfil, Luis Manuel Molinos-Albert, Ana Barajas, Anna Pons-Grífols, Carlos Ávila-Nieto, Ismael Varela, Laura Cervera, Sònia Gutiérrez-Granados, María Mercedes Segura, Francesc Gòdia, Bonaventura Clotet, Jorge Carrillo, Julià Blanco
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-13 (2023)
Abstract Antigen display on the surface of Virus-Like Particles (VLPs) improves immunogenicity compared to soluble proteins. We hypothesised that immune responses can be further improved by increasing the antigen density on the surface of VLPs. In th
Externí odkaz:
https://doaj.org/article/20b68eeb7d6f4ecfa2c0a0005799608d
Autor:
Eudald Felip, Edwards Pradenas, Margarita Romeo, Silvia Marfil, Benjamin Trinité, Víctor Urrea, Ainhoa Hernández, Ester Ballana, Marc Cucurull, Lourdes Mateu, Marta Massanella, Bonaventura Clotet, Teresa Morán, Julià Blanco
Publikováno v:
Molecular Oncology, Vol 17, Iss 4, Pp 686-694 (2023)
Patients with solid tumors have been a risk group since the beginning of the SARS‐CoV‐2 pandemic due to more significant complications, hospitalizations or deaths. The immunosuppressive state of cancer treatments or the tumor itself could influen
Externí odkaz:
https://doaj.org/article/cb23f6b2bc0042d091babfcdf72a34a2
Autor:
Carlos Ávila-Nieto, Júlia Vergara-Alert, Pep Amengual-Rigo, Erola Ainsua-Enrich, Marco Brustolin, María Luisa Rodríguez de la Concepción, Núria Pedreño-Lopez, Jordi Rodon, Victor Urrea, Edwards Pradenas, Silvia Marfil, Ester Ballana, Eva Riveira-Muñoz, Mònica Pérez, Núria Roca, Ferran Tarrés-Freixas, Julieta Carabelli, Guillermo Cantero, Anna Pons-Grífols, Carla Rovirosa, Carmen Aguilar-Gurrieri, Raquel Ortiz, Ana Barajas, Benjamin Trinité, Rosalba Lepore, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, Nuria Izquierdo-Useros, Alfonso Valencia, Julià Blanco, Bonaventura Clotet, Victor Guallar, Joaquim Segalés, Jorge Carrillo
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Most COVID-19 vaccines are based on the SARS-CoV-2 Spike glycoprotein (S) or their subunits. However, S shows some structural instability that limits its immunogenicity and production, hampering the development of recombinant S-based vaccines. The in
Externí odkaz:
https://doaj.org/article/8d145e1f4f964517b358c973214ef36f